Futura Medical, a transdermal technology specialist, has received by an European regulator clarity on the regulatory pathways for its two topical pain relief products, TPR100 (diclofenac) and TIB200 (ibuprofen).
Futura Medical’s pivotal efficacy study of MED2002, a novel gel for the treatment of erectile dysfunction (ED) is underway and recruitment of patients for the study is proceeding well, with 118 patients having enrolled in the study to date.